Forecast Of The Day: Abbott’s Nutritionals Revenue
What?
Abbott’s (NYSE:ABT) Nutritionals Revenue has risen from around $7.4 billion in 2019 to about $7.7 billion in 2020. Trefis expects the metric to rise to about $8.4 billion in 2021 and to about $8.7 billion in 2022.
Why?
- After Nearly A 20% Rise In Six Months Will Abbott Stock See Higher Levels Post Q1?
- What’s Next For Abbott Stock After A 6% Rise This Year?
- Is Abbott Stock Undervalued At $95?
- Which Is A Better Pick – Abbott Stock Or Amgen?
- Is Abbott Stock A Better Healthcare Pick Over Thermo Fisher Scientific?
- Lower Testing Demand To Weigh On Abbott’s Q2?
We expect growth to be driven by higher demand from emerging markets and the company’s investments into new product development.
So What?
We think the projected growth is largely priced into ABT stock. We value ABT at about $142 per share, roughly in line with the current market price.
See Our Complete Analysis For Abbott
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
| Returns | Dec 2021 MTD [1] |
2021 YTD [1] |
2017-21 Total [2] |
| ABT Return | 6% | 23% | 251% |
| S&P 500 Return | -3% | 21% | 104% |
| Trefis MS Portfolio Return | -1% | 42% | 283% |
[1] Month-to-date and year-to-date as of 12/20/2021
[2] Cumulative total returns since 2017